- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$353.93 MnMarket Estimate, 2026
$406.31 MnMarket Forecast, 2034
$1,226 MnCAGR, 2026–2034
14.8%Executive Summary: Asia-Pacific Digital Breast Tomosynthesis (DBT) Equipment Market
- Market Scope: Comprehensive regional analysis of the Asia-Pacific digital breast tomosynthesis (DBT) equipment market, covering standalone DBT equipment and 3-D upgradation systems deployed across hospitals and diagnostic centers for advanced breast cancer screening and diagnostics.
- Market Valuation: Valued at USD 353.93 million in 2025, reaching USD 406.31 million in 2026, and anticipated to expand to USD 1,226 million by 2034, growing at a robust CAGR of 14.8% during the forecast period (2026 to 2034).
- Primary Growth Drivers: Escalating global and regional prevalence of breast cancer among aging female populations, rising government and non-profit breast cancer awareness campaigns, and technological advancements focusing on improved cancer detection rates with minimized callback rates.
Key Market Segment Metrics
| Category | Leading Segment (Base Position) | Fastest-Growing / High-Growth Segment |
|---|---|---|
| By Product | DBT Equipment (dominated market share as primary standalone units installed in new imaging facilities) | 3-D Upgradation Systems (high-growth segment allowing existing 2D mammography facilities to cost-effectively upgrade to tomosynthesis) |
| By End User | Hospitals (commanded the largest market share due to high patient volumes, advanced infrastructure, and multi-specialty cancer care) | Diagnostic Centers (rapidly expanding outpatient segment driven by accessibility and specialized imaging service providers) |
| By Country | China (largest regional market share driven by advanced healthcare infrastructure, large female demographic, and rising cancer incidence) | India & Japan (steady high-growth markets propelled by increasing breast cancer prevalence and government screening initiatives) |
Major Market Players & Industry Landscape
Market Structure: Competitive regional ecosystem comprising global medical imaging giants and specialized diagnostic equipment manufacturers competing through technological innovations, image resolution enhancements, and hospital network partnerships.
Key Companies: Hologic Inc., Siemens Healthineers, Fujifilm Corporation, GE Healthcare, Internazionale Medico Scientifica S.r.l., and Planmed Oy.
Download Free Sample Report
Asia-Pacific Digital Breast Tomosynthesis Equipment Market Size
The Asia-Pacific digital breast tomosynthesis (DBT) equipment market was valued at USD 353.93 million in 2025, is estimated to reach USD 406.31 million in 2026, and is projected to reach USD 1,226 million by 2034, growing at a CAGR of 14.8% from 2026 to 2034.
MARKET DRIVERS
Rising Breast Cancer Cases and Awareness Campaigns Drive Adoption of Screening Technologies
The increasing prevalence of breast cancer will lead to the market's growth during the projected period. According to Breastcancer.org, in 2019, 268,650 new cases of invasive breast cancer are expected to be diagnosed in women, along with 62,950 new cases of non-invasive breast cancer. In addition, the increase in government initiatives to promote awareness of breast cancer treatment and the growing female population are other key factors responsible for the growth of the market in the APAC region.
According to the World Health Organization (WHO), breast cancer is the most common type of cancer in women worldwide; around 2.15 million women have breast cancer each year, with the highest number of deaths recorded among women due to cancer. In 2018, an estimated 627,500 women died from breast cancer, accounting for almost 15.69% of all cancer deaths among women worldwide.
Increasing breast cancer screening and minimal radiation exposure procedures are other factors that will drive the market. DBT screening improves breast cancer detection rates and reduces callbacks that raise the patients' prognosis. During a DBT procedure, patients are exposed to higher radiation levels than with 2D mammography. Hence, a decrease in radiation exposure is expected to provide lucrative growth opportunities for players in the market. Regulators should also define the use of DBT in breast cancer screening and its role in diagnosing and staging cancer.
MARKET RESTRAINTS
Lack of clinical trials supporting the efficacy of DBT will hamper the growth of the APAC digital breast tomosynthesis (DBT) Equipment market. In addition, lack of devices or skilled labor to perform the procedure coupled with poor healthcare facilities in developing/under-developed countries in the APAC region will challenge the market growth.
REPORT COVERAGE
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Product, End-user, and Region. |
| Various Analyses Covered | Global, Regional and Country-Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Countries Covered | India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore, Rest of APAC |
| Market Leaders Profiled | Hologic Inc., Siemens Healthineers, Fujifilm Corporation. Other players in the market include GE Healthcare, Internazionale Medico Scientifica S.r.l. and Planmed Oy. |
COUNTRY LEVEL ANALYSIS
In 2024, the China digital breast tomosynthesis equipment market accounted for the largest share in terms of revenue of the APAC digital breast tomosynthesis (DBT) Equipment market. This regional market growth can be linked to advanced healthcare infrastructure, a sizeable female population, disposable income, a high incidence of breast cancer, and a growing demand for digital technology. In 2018, the incidence of breast cancer was 36.18 and 84.94 per 100,000 in China and the United States, respectively. Breast cancer mortality in 2019 was 8.85 and 12.76 per 100,000 in China and the United States, respectively. Therefore, the Chinese market is projected to grow faster in terms of profits during the forecast period.
Over the forecast period, India and Japan are predicted to have a steady growth rate due to the growing number of breast cancer cases in these regions. Breast cancer has been ranked as the number one cancer among Indian women, with a rate of 25.88 per 100,000 women and a mortality of 12.73 per 100,000 women. In 2020, the highest number of breast cancer cases among women in Japan was over 90,000. The estimated number of cancer incidences among Japanese women that year was around 430,000 cases.
KEY MARKET PLAYERS
Companies playing a leading role in the Asia-Pacific Digital Breast Tomosynthesis (Dbt) Equipment Market Profiled in the Report are Hologic Inc., Siemens Healthineers, Fujifilm Corporation. Other players in the market include GE Healthcare, Internazionale Medico Scientifica S.r.l. and Planmed Oy.
MARKET SEGMENTATION
This research report on the Asia-Pacific Digital Breast Tomosynthesis (DBT) Equipment Market has been segmented and sub-segmented into the following categories.
By Product
- 3-D Upgradation
- DBT Equipment
By End User
- Hospitals
- Diagnostic centres
By Country
- India
- China
- Japan
- South Korea
- Australia
- New Zealand
- Thailand
- Malaysia
- Vietnam
- Philippines
- Indonesia
- Singapore
- Rest of APAC